Madeleine Duvic

List of Publications by Citations

352 papers	19,940 citations	73 h-index	133 g-index
363 ext. papers	22,508 ext. citations	4 avg, IF	6.45 L-index

#	Paper	IF	Citations
352	Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood*, **2007**, 110, 1713-22	2.2	1012
351	Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). *Blood*, **2007**, 109, 31-9	2.2	924
350	Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2007**, 25, 3109-15	2.2	835
349	Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. *Journal of Clinical Oncology*, **2001**, 19, 2456-71	2.2	562
348	Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2001**, 19, 376-88	2.2	534
347	Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2010**, 28, 4485-91	2.2	502
346	Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. *Nature*, **2010**, 466, 113-7	50.4	500
345	Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. *Journal of Clinical Oncology*, **2011**, 29, 2598-607	2.2	407
344	Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. *Journal of the American Academy of Dermatology*, **2002**, 46, 95-106	4.5	374
343	Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. *Journal of Cell Biology*, **1988**, 107, 427-46	7.3	326
342	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. *Lancet, The*, **2017**, 390, 555-566	40	303
341	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. *Blood*, **2011**, 118, 4024-35	2.2	295
340	Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. *Archives of Dermatology*, **2001**, 137, 581-93		256
339	Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. *Expert Opinion on Investigational Drugs*, **2007**, 16, 1111-20	5.9	248
338	Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis. *Blood*, **1998**, 92, 1150-1159	2.2	243
337	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 1192-1204	21.7	239
336	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. *Journal of Clinical Oncology*, **2015**, 33, 3766-73	2.2	237

335	Central hypothyroidism associated with retinoid X receptor-selective ligands. *New England Journal of Medicine*, **1999**, 340, 1075-9	59.2	237
334	Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. *Journal of Clinical Oncology*, **2015**, 33, 3759-65	2.2	203
333	Genomic profiling of S□ary syndrome identifies alterations of key T cell signaling and differentiation genes. *Nature Genetics*, **2015**, 47, 1426-34	36.3	199
332	Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. *Journal of Investigative Dermatology* , **2005**, 125, 1045-52	4.3	198
331	Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. *Journal of Investigative Dermatology*, **1997**, 109, 91-5	4.3	194
330	Association of Erythrodermic Cutaneous T-Cell Lymphoma, Superantigen-Positive Staphylococcus aureus, and Oligoclonal T-Cell Receptor V□Gene Expansion. *Blood*, **1997**, 89, 32-40	2.2	191
329	Long-term outcomes of 1,263 patients with mycosis fungoides and S□ary syndrome from 1982 to 2009. *Clinical Cancer Research*, **2012**, 18, 5051-60	12.9	188
328	Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. *Journal of Clinical Oncology*, **2010**, 28, 1870-7	2.2	179
327	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. *New England Journal of Medicine*, **2019**, 380, 1628-1637	59.2	173
326	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. *Blood*, **2007**, 109, 4655-62	2.2	168
325	Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. *Blood*, **2015**, 125, 1883-9	2.2	165
324	A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. *Blood*, **2004**, 104, 328-35	2.2	153
323	Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. *American Journal of Clinical Pathology*, **2001**, 115, 885-92	1.9	153
322	Optimizing bexarotene therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **2002**, 47, 672-84	4.5	142
321	Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. *Journal of the American Academy of Dermatology*, **1997**, 37, 85-92	4.5	141
320	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. *Journal of Cutaneous Pathology*, **2017**, 44, 158-176	1.7	135
319	Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. *Archives of Dermatology*, **2002**, 138, 325-32		134
318	S□ary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). *Journal of the American Academy of Dermatology*, **2011**, 64, 352-404	4.5	133

317	Prognostic factor analysis in mycosis fungoides/Sézary syndrome. *Journal of the American Academy of Dermatology*, **1999**, 40, 914-24	4.5	133
316	Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14811-5	11.5	132
315	A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. *British Journal of Haematology*, **2015**, 168, 811-9	4.5	131
314	Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. *British Journal of Dermatology*, **2008**, 159, 105-12	4	130
313	Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. *British Journal of Haematology*, **2018**, 183, 428-444	4.5	129
312	HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6532-7	11.5	129
311	Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. *Journal of Clinical Oncology*, **2010**, 28, 2365-72	2.2	122
310	History of atopy or autoimmunity increases risk of alopecia areata. *Journal of the American Academy of Dermatology*, **2009**, 61, 581-91	4.5	120
309	Photopheresis therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **1996**, 35, 573-9	4.5	120
308	Cutaneous □T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. *American Journal of Surgical Pathology*, **2012**, 36, 1656-65	6.7	119
307	Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. *Clinical Lymphoma and Myeloma*, **2006**, 7, 51-8		119
306	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. *Journal of the American Academy of Dermatology*, **2015**, 72, 286-92	4.5	117
305	Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. *Blood*, **2002**, 100, 3369-73	12	113
304	Response of psoriasis to a new topical retinoid, AGN 190168. *Journal of the American Academy of Dermatology*, **1994**, 30, 581-90	4.5	112
303	The optimal use of bexarotene in cutaneous T-cell lymphoma. *British Journal of Dermatology*, **2007**, 157, 433-40	4	111
302	Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. *European Journal of Cancer*, **2013**, 49, 386-94	7.5	104
301	Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. *Blood*, **2012**, 119, 4115-22	2.2	104
300	Alopecia areata and cytomegalovirus infection in twins: genes versus environment?. *Journal of the American Academy of Dermatology*, **1998**, 38, 418-25	4.5	101

299	Review of the treatment of mycosis fungoides and sZary syndrome: a stage-based approach. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2008**, 6, 436-42	7.3	97
298	Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. *Blood*, **2007**, 110, 3015-27	2.2	96
297	Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. *Journal of Investigative Dermatology*, **1996**, 106, 269-74	4.3	96
296	Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and ReiterM syndrome: a disease continuum?. *Arthritis and Rheumatism*, **1990**, 33, 1574-8		94
295	Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. *International Journal of Dermatology*, **2009**, 48, 243-52	1.7	92
294	Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. *Journal of Clinical Oncology*, **1999**, 17, 3117-21	2.2	88
293	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. *European Journal of Cancer*, **2013**, 49, 2859-68	7.5	87
292	CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **2006**, 126, 575-83	4.3	87
291	In vivo fluorescence spectroscopy and imaging of human skin tumours. *Lasers in Medical Science*, **1994**, 9, 191-201	3.1	87
290	Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. *Cancer Research*, **2004**, 64, 7361-9	10.1	84
289	Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. *Journal of the American Academy of Dermatology*, **2016**, 74, 59-67	4.5	81
288	Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patientsM PBMCs: potential role for STAT-3 and NF-kappaB signaling. *Journal of Investigative Dermatology*, **2010**, 130, 2110-9	4.3	81
287	Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). *Clinical Lymphoma and Myeloma*, **2002**, 2, 222-8		80
286	Combined modality therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **1996**, 34, 1022-9	4.5	80
285	Human leukocyte antigen-DQB1*03 alleles are associated with alopecia areata. *Journal of Investigative Dermatology*, **1994**, 103, 758-63	4.3	80
284	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology* , **2010**, 63, 975-83	4.5	79
283	Molecular mechanisms of tazarotene action in psoriasis. *Journal of the American Academy of Dermatology*, **1997**, 37, S18-S24	4.5	78
282	Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. *Clinical and Experimental Dermatology*, **2009**, 34, 576-81	1.8	74

281	Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. *Clinical Lymphoma and Myeloma*, **2009**, 9, 412-6		74
280	Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. *Cell Cycle*, **2014**, 13, 3331-5	4.7	73
279	A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. *Clinical Cancer Research*, **2009**, 15, 6217-24	12.9	73
278	Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? [see comments]. *Blood*, **1995**, 86, 651-658	2.2	72
277	HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. *Journal of Investigative Dermatology*, **1996**, 107, 373-6	4.3	71
276	The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. *American Journal of Clinical Pathology*, **2001**, 115, 413-21	1.9	70
275	Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. *Blood*, **2003**, 101, 2132-6	2.2	67
274	Alopecia areata in families: association with the HLA locus. *Journal of Investigative Dermatology Symposium Proceedings*, **1999**, 4, 220-3	1.1	67
273	Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. *Cancer*, **2004**, 100, 342-9	6.4	66
272	Treatment of cutaneous T-cell lymphoma with retinoids. *Dermatologic Therapy*, **2006**, 19, 264-71	2.2	64
271	Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. *Annals of Oncology*, **2015**, 26, 2490-5	10.3	63
270	Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. *Blood*, **2014**, 123, 1159-66	2.2	61
269	Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. *Blood*, **1997**, 89, 32-40	2.2	61
268	Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. *Dermatologic Therapy*, **2003**, 16, 322-30	2.2	59
267	Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **2003**, 49, 35-49	4.5	58
266	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non- Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Blood*, **1996**, 88, 1771-1779	2.2	57
265	Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. *Journal of the American Academy of Dermatology*, **2014**, 71, 1117-26	4.5	55
264	CD30+ neoplasms of the skin. *Current Hematologic Malignancy Reports*, **2011**, 6, 245-50	4.4	55

263	Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. *Journal of the American Academy of Dermatology*, **2009**, 60, 231-5	4.5	55
262	HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. *Future Medicinal Chemistry*, **2012**, 4, 471-86	4.1	54
261	Treatment of cutaneous T cell lymphoma: current status and future directions. *American Journal of Clinical Dermatology*, **2002**, 3, 193-215	7.1	54
260	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. *Blood*, **1994**, 84, 733-738	2.2	53
259	Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators. *OncoImmunology*, **2017**, 6, e1306618	7.2	52
258	DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. *American Journal of Hematology*, **1998**, 58, 87-90	7.1	52
257	A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. *Journal of the American Academy of Dermatology*, **2006**, 55, 807-13	4.5	52
256	Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). *Leukemia and Lymphoma*, **2002**, 43, 121-6	1.9	52
255	Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. *Clinical Cancer Research*, **2000**, 6, 3249-59	12.9	52
254	Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. *Archives of Dermatology*, **2000**, 136, 1461-9		51
253	Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. *EBioMedicine*, **2016**, 7, 240-7	8.8	51
252	Serum T helper 1 cytokine levels are greater in patients with alopecia areata regardless of severity or atopy. *Clinical and Experimental Dermatology*, **2010**, 35, 409-16	1.8	50
251	A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. *BMC Clinical Pathology*, **2002**, 2, 5	3	50
250	Emerging new therapies for cutaneous T-cell lymphoma. *Dermatologic Clinics*, **2000**, 18, 147-56	4.2	50
249	Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V beta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides?. *Journal of the American Academy of Dermatology*, **1997**, 37, 828-31	4.5	49
248	Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. *Journal of the American Academy of Dermatology*, **2004**, 50, 600-7	4.5	49
247	Prevalence and severity of pruritus in cutaneous T cell lymphoma. *International Journal of Dermatology*, **2012**, 51, 930-4	1.7	48
246	Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. *Vaccine Journal*, **1999**, 6, 79-84		48

245	Optimizing denileukin diftitox (Ontak) therapy. *Future Oncology*, **2008**, 4, 457-69	3.6	46
244	Primary cutaneous B-cell lymphoma. *Journal of the American Academy of Dermatology*, **2005**, 53, 479-84	4.5	46
243	The role for interleukin-12 therapy of cutaneous T cell lymphoma. *Annals of the New York Academy of Sciences*, **2001**, 941, 177-84	6.5	44
242	Vorinostat in cutaneous T-cell lymphoma. *Drugs of Today*, **2007**, 43, 585-99	2.5	43
241	Primary Cutaneous T-Cell Lymphomas Showing Gamma-Delta (δ) Phenotype and Predominantly Epidermotropic Pattern are Clinicopathologically Distinct From Classic Primary Cutaneous αβ T-Cell Lymphomas. *American Journal of Surgical Pathology*, **2017**, 41, 204-215	6.7	41
240	The pathogenesis of psoriasis and the mechanism of action of tazarotene. *Journal of the American Academy of Dermatology*, **1998**, 39, S129-33	4.5	41
239	Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. *Clinical Cancer Research*, **2001**, 7, 2682-92	12.9	41
238	The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. *Cancer Treatment Reviews*, **2016**, 43, 58-66	14.4	40
237	Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 49-56	2	38
236	Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. *Journal of Investigative Dermatology*, **2005**, 124, 741-50	4.3	38
235	Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 358-363	2	37
234	The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. *Journal of the American Academy of Dermatology*, **2011**, 64, 53-63	4.5	37
233	Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. *Journal of Investigative Dermatology*, **2008**, 128, 2728-2735	4.3	37
232	Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. *Cancer*, **2015**, 121, 1993-2003	6.4	34
231	Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. *Leukemia and Lymphoma*, **2013**, 54, 284-9	1.9	34
230	Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. *Cancer*, **2013**, 119, 825-31	6.4	34
229	Analysis of HLA-D locus alleles in alopecia areata patients and families. *Journal of Investigative Dermatology*, **1995**, 104, 5S-6S	4.3	34
228	Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. *Haematologica*, **2015**, 100, 794-800	6.6	33

227	Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. *Cancer Medicine*, **2015**, 4, 1440-7	4.8	33
226	Mycosis fungoides: pathophysiology and emerging therapies. *Seminars in Oncology*, **2007**, 34, S21-8	5.5	33
225	Extracorporeal Photopheresis for the Treatment of Cutaneous T-Cell Lymphoma. *Journal of Cutaneous Medicine and Surgery*, **2003**, 7, 3-7	1.6	33
224	Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. *Journal of Investigative Dermatology*, **2003**, 121, 902-9	4.3	33
223	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). *Annals of Oncology*, **2014**, 25, 1807-1812	10.3	32
222	Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatology Photoimmunology and Photomedicine*, **2012**, 28, 250-7	2.4	32
221	Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. *Blood* , **1998**, 92, 1150-9	2.2	31
220	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e83-93	2	30
219	Multicenter photopheresis intervention trial in early-stage mycosis fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 219-27	2	30
218	Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. *Hematology/Oncology Clinics of North America*, **2003**, 17, 1405-19	3.1	30
217	Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. *American Journal of Clinical Dermatology*, **2016**, 17, 319-27	7.1	30
216	Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. *Human Pathology*, **2015**, 46, 558-69	3.7	29
215	Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. *Journal of Cutaneous Pathology*, **2016**, 43, 1161-1166	1.7	29
214	ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. *Cancer Cell*, **2016**, 29, 874-888	24.3	29
213	Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 377-84	2	29
212	Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. *International Journal of Dermatology*, **2003**, 42, 116-22	1.7	29
211	HLA-D Locus Associations in Alopecia Areata. *Archives of Dermatology*, **1991**, 127, 64		29
210	Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. *Blood*, **2011**, 117, 3382-90	2.2	28

209	Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. *Clinical Cancer Research*, **2004**, 10, 5587-94	12.9	28
208	Cloning and characterization of a novel epidermal cell surface antigen (ESA).. *Journal of Biological Chemistry*, **1994**, 269, 19983-19991	5.4	28
207	Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, e105-12	2	27
206	Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. *British Journal of Cancer*, **2006**, 95, S13-S19	8.7	27
205	Persistent atypical lymphocytic hyperplasia following tick bite in a child: report of a case and review of the literature. *Pediatric Dermatology*, **2001**, 18, 481-4	1.9	27
204	Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. *Biologics: Targets and Therapy*, **2007**, 1, 377-92	4.4	27
203	Skin directed therapy for mycosis fungoides: a review. *Journal of Drugs in Dermatology*, **2008**, 7, 655-66	2.2	27
202	Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. *Journal of Cutaneous Pathology*, **2016**, 43, 1121-1130	1.7	26
201	Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. *Therapeutic Advances in Hematology*, **2016**, 7, 171-4	5.7	26
200	High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. *Melanoma Research*, **2006**, 16, 461-3	3.3	26
199	Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. *Dermatologic Clinics*, **2015**, 33, 757-64	4.2	25
198	Increased malignancy risk in the cutaneous T-cell lymphoma patient population. *Clinical Lymphoma and Myeloma*, **2008**, 8, 100-5		25
197	Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 2205-8	5.6	25
196	Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. *Journal of Cutaneous Medicine and Surgery*, **2003**, 7, 3-7	1.6	25
195	Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formation **1999**, 75, 147-159		25
194	Cloning and characterization of a novel epidermal cell surface antigen (ESA). *Journal of Biological Chemistry*, **1994**, 269, 19983-91	5.4	25
193	High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. *JCI Insight*, **2018**, 3,	9.9	25
192	The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. *Journal of Investigative Dermatology* , **2004**, 123, 380-7	4.3	24

191	Effectiveness of photopheresis in Sézary syndrome. *Archives of Dermatology*, **1999**, 135, 995-7		24
190	Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome. *Journal of Cutaneous Pathology*, **2012**, 39, 500-7	1.7	23
189	Human leukocyte antigen class II alleles are associated with risk of alopecia areata. *Journal of Investigative Dermatology*, **2008**, 128, 240-3	4.3	23
188	EGFR inhibitor-associated acneiform folliculitis: assessment and management. *American Journal of Clinical Dermatology*, **2008**, 9, 285-94	7.1	23
187	Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas. *Journal of the American Academy of Dermatology*, **2004**, 51, 200-4	4.5	23
186	Blue rubber bleb nevus syndrome: laser photocoagulation of colonic hemangiomas in a child with microcytic anemia. *Pediatric Dermatology*, **1992**, 9, 91-4	1.9	23
185	Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. *Archives of Dermatological Research*, **2017**, 309, 453-459	3.3	22
184	Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. *OncoImmunology*, **2015**, 4, e1011524	7.2	22
183	Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. *OncoImmunology*, **2016**, 5, e1175799	7.2	22
182	Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. *Journal of Investigative Dermatology*, **2008**, 128, 2631-2639	4.3	22
181	The genetics of alopecia areata. *Clinics in Dermatology*, **2001**, 19, 135-9	3	22
180	Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment. *International Journal of Dermatology*, **2001**, 40, 505-11	1.7	21
179	Keratinocyte transglutaminase expression varies in squamous cell carcinomas. *Journal of Investigative Dermatology*, **1994**, 102, 462-9	4.3	21
178	Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. *JAMA Dermatology*, **2017**, 153, 1302-1306	5.1	20
177	Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature. *Journal of the American Academy of Dermatology*, **2015**, 73, 976-86	4.5	20
176	Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. *Clinical Cancer Research*, **2017**, 23, 1299-1311	12.9	20
175	Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. *Clinical Cancer Research*, **2017**, 23, 3552-3556	12.9	19
174	Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. *Leukemia and Lymphoma*, **2013**, 54, 69-75	1.9	19

173	Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. *Clinical Lymphoma and Myeloma*, **2000**, 1 Suppl 1, S51-5		19
172	Tumor necrosis factor-alpha and interferon-gamma, but not HTLV-I tax, are likely factors in the epidermotropism of cutaneous T-cell lymphoma via induction of interferon-inducible protein-10. *Leukemia and Lymphoma*, **1998**, 29, 315-28	1.9	19
171	Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma (CTCL): Results of a phase IIb trial. *Journal of Clinical Oncology*, **2006**, 24, 7500-7500	2.2	19
170	Augmentation of blood dendritic cells by extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma and graft-versus-host disease. *Journal of Investigative Dermatology*, **2013**, 133, 2098-100	4.3	18
169	Primary and metastatic malignant tumors of the scalp: an update. *American Journal of Clinical Dermatology*, **2010**, 11, 233-46	7.1	18
168	Efficacy and safety of topical tazarotene: a review. *Expert Opinion on Drug Metabolism and Toxicology*, **2009**, 5, 195-210	5.5	18
167	Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. *Journal of the American Academy of Dermatology*, **2008**, 59, S16-22	4.5	18
166	Alopecia areata registry: an overview. *Journal of Investigative Dermatology Symposium Proceedings*, **2003**, 8, 219-21	1.1	18
165	Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. *Leukemia and Lymphoma*, **2018**, 59, 880-887	1.9	16
164	BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression. *Human Pathology*, **2016**, 50, 79-89	3.7	16
163	Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. *OncoImmunology*, **2018**, 7, e1467856	7.2	16
162	Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox. *Clinical Lymphoma and Myeloma*, **2008**, 8, 55-8		16
161	ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-B pathways. *Oncotarget*, **2017**, 8, 61761-61776	3.3	16
160	Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 297-304	2	15
159	Pulmonary manifestations in patients with cutaneous T-cell lymphomas. *Cancer*, **2007**, 109, 1550-5	6.4	15
158	Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, 637-643	2	15
157	Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. *American Journal of Clinical Dermatology*, **2019**, 20, 115-122	7.1	15
156	United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. *Journal of the American Academy of Dermatology*, **2020**, 83, 703-704	4.5	15

155	Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. *Clinical Cancer Research*, **1997**, 3, 169-77	12.9	15
154	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and S□ary Syndrome: A Multi-institutional and International Pathology Study. *American Journal of Surgical Pathology*, **2018**, 42, 726-734	6.7	14
153	The effect of extracorporeal photopheresis alone or in combination therapy on circulating CD4(+) Foxp3(+) CD25(-) T cells in patients with leukemic cutaneous T-cell lymphoma. *Photodermatology Photoimmunology and Photomedicine*, **2015**, 31, 184-94	2.4	14
152	Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. *Expert Review of Clinical Pharmacology*, **2014**, 7, 591-7	3.8	14
151	Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. *Journal of Dermatological Treatment*, **2017**, 28, 567-569	2.8	13
150	Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. *Leukemia and Lymphoma*, **2015**, 56, 2847-54	1.9	13
149	Vitamin D deficiency in mycosis fungoides and S□ary syndrome patients is similar to other cancer patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, 518-24	2	13
148	T-cell receptor-□n gamma-delta phenotype cutaneous T-cell lymphoma can be accompanied by atypical expression of CD30, CD4, or TCR□1 and an indolent clinical course. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14, e195-200	2	13
147	Reed syndrome presenting with leiomyosarcoma. *JAAD Case Reports*, **2015**, 1, 150-2	1.4	13
146	Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/S□ary syndrome receiving placebo. *Journal of the American Academy of Dermatology*, **2012**, 67, 867-75	4.5	13
145	Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. *Expert Opinion on Investigational Drugs*, **1997**, 6, 1537-51	5.9	13
144	Therapy options in cutaneous T-cell lymphoma. *Expert Review of Anticancer Therapy*, **2001**, 1, 403-20	3.5	13
143	Childhood alopecia areata-Data from the National Alopecia Areata Registry. *Pediatric Dermatology*, **2018**, 35, 164-169	1.9	12
142	A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2016**, 16, e15-9	2	12
141	TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform. *Frontiers in Medicine*, **2017**, 4, 153	4.9	12
140	Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. *Clinical Lymphoma, Myeloma and Leukemia*, **2012**, 12, 180-5	2	12
139	Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 514-9	1.9	12
138	Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 286-8	2	12

137	Increased serum immunoglobulin levels are common in mycosis fungoides and Sézary syndrome. *Journal of the American Academy of Dermatology*, **2002**, 47, 685-91	4.5	12
136	Cytokine expression patterns distinguish HIV associated skin diseases. *Experimental Dermatology*, **2000**, 9, 341-50	4	12
135	Epidermal surface antigen (MS17S1) is highly conserved between mouse and human. *Genomics*, **1995**, 27, 251-8	4.3	12
134	Emergence of leprosy in a patient with mycosis fungoides. *Journal of the American Academy of Dermatology*, **1994**, 30, 313-5	4.5	12
133	Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T-cell lymphoma. *Journal of the European Academy of Dermatology and Venereology*, **2018**, 32, 1652-1656	4.6	12
132	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Blood*, **1996**, 88, 1771-9	2.2	12
131	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. *European Journal of Cancer*, **2020**, 133, 120-130	7.5	11
130	How to Discern Folliculotropic Mycosis Fungoides From Follicular Mucinosis Using a Pediatric Case. *Journal of Cutaneous Medicine and Surgery*, **2018**, 22, 336-340	1.6	11
129	Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13´years after denileukin diftitox. *JAAD Case Reports*, **2017**, 3, 501-504	1.4	11
128	Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. *Hematology American Society of Hematology Education Program*, **2015**, 2015, 529-44	3.1	11
127	Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. *Clinical Lymphoma and Myeloma*, **2004**, 5, 190-3		11
126	Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy. *American Journal of Clinical Dermatology*, **2003**, 4, 429-33	7.1	11
125	Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation. *International Journal of Dermatology*, **2016**, 55, e539-43	1.7	11
124	Immunophenotypic Shifts in Primary Cutaneous T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. *American Journal of Surgical Pathology*, **2017**, 41, 431-445	6.7	10
123	The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning. *Journal of Investigative Dermatology Symposium Proceedings*, **2018**, 19, S41-S46	1.1	10
122	A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. *International Journal of Dermatology*, **2013**, 52, 1111-4	1.7	10
121	Cutaneous T-cell lymphoma. *Journal of the American Academy of Dermatology*, **2004**, 51, S43-5	4.5	10
120	Cutaneous T-cell lymphoma. New immunomodulators. *Dermatologic Clinics*, **2001**, 19, 737-48	4.2	10

119	Expression of pemphigus vulgaris antigen in cultured human keratinocytes: effect of inhibitors, tunicamycin, and lectins. *Journal of Investigative Dermatology*, **1988**, 90, 708-15	4.3	10
118	Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.. *Blood*, **2006**, 108, 2467-2467	2.2	10
117	Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study. *Blood*, **2016**, 128, 182-182	2.2	10
116	Differential expression of CCR4 in primary cutaneous gamma/delta (γδ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. *Journal of Dermatological Science*, **2018**, 89, 88-91	4.3	9
115	Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. *American Journal of Hematology*, **2011**, 86, 627-30	7.1	9
114	Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. *Leukemia and Lymphoma*, **1996**, 24, 103-10	1.9	9
113	Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity. *Clinical Lymphoma and Myeloma*, **2000**, 1, 141-5		9
112	The gene for a novel epidermal antigen maps near the neurofibromatosis 1 gene. *Genomics*, **1992**, 14, 369-76	4.3	9
111	A case of indeterminate dendritic cell tumor presenting with leonine facies. *Journal of Cutaneous Pathology*, **2016**, 43, 158-63	1.7	9
110	Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine. *Oncology*, **2007**, 73, 130-5	3.6	8
109	Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. *Clinical Lymphoma and Myeloma*, **2006**, 6, 488-92		8
108	Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. *Cytometry Part B - Clinical Cytometry*, **2021**, 100, 183-191	3.4	8
107	The "Duvic regimen" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sézary syndrome. *International Journal of Dermatology*, **2018**, 57, 123-124	1.7	8
106	Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. *Oncology*, **2007**, 21, 33-40	1.8	8
105	Dendritic cells and cutaneous T-cell lymphomas. *Giornale Italiano Di Dermatologia E Venereologia*, **2011**, 146, 103-13	0.8	8
104	Primär kutane CD30(+) lymphoproliferative Erkrankungen. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 767-84	1.2	7
103	Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. *International Journal of Dermatology*, **2009**, 48, 598-602	1.7	7
102	The human gene for an epidermal surface antigen (M17S1) is located at 17q11-12. *Genomics*, **1991**, 11, 481-2	4.3	7

101	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. *Blood*, **1994**, 84, 733-8	2.2	7
100	Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. *Archives of Dermatological Research*, **2020**, 312, 283-288	3.3	7
99	Teledermatology During COVID-19: An Updated Review. *American Journal of Clinical Dermatology*, **2021**, 22, 467-475	7.1	7
98	Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. *Case Reports in Dermatological Medicine*, **2016**, 2016, 5857935	0.8	7
97	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 97-105	2	7
96	Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides. *Dermatologic Therapy*, **2017**, 30, e12485	2.2	6
95	Granulomatous Mycosis Fungoides in an Adolescent-A Rare Encounter and Review of the Literature. *Pediatric Dermatology*, **2016**, 33, e296-8	1.9	6
94	Coexistent psoriasis and lupus erythematosus treated with alefacept. *American Journal of Clinical Dermatology*, **2007**, 8, 47-50	7.1	6
93	Long-term control of mycosis fungoides of the hands with topical bexarotene. *International Journal of Dermatology*, **2003**, 42, 238-41	1.7	6
92	Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. *Clinical Lymphoma and Myeloma*, **2000**, 1 Suppl 1, S15-20		6
91	Werner's syndrome. *Dermatologic Clinics*, **1995**, 13, 163-8	4.2	6
90	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. *European Journal of Cancer*, **2021**, 148, 411-421	7.5	6
89	Forodesine in the treatment of cutaneous T-cell lymphoma. *Expert Opinion on Investigational Drugs*, **2017**, 26, 771-775	5.9	5
88	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. *Advances in Radiation Oncology*, **2017**, 2, 363-369	3.3	5
87	Oral bexarotene for post-transplant cutaneous T-cell lymphoma. *Dermatologic Therapy*, **2017**, 30, e12524	2.2	5
86	Novel Mutations Involving NF-κB and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome. *Journal of Investigative Dermatology*, **2017**, 137, 1831-1833	4.3	5
85	The sign of Leser-Trélat. *Medical and Pediatric Oncology*, **1997**, 28, 234-7		5
84	Mycosis fungoides with coccidioidomycosis. *Clinical Lymphoma and Myeloma*, **2006**, 7, 148-50		5

83	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. *Blood Advances*, **2021**, 5, 5098-5106	7.8	5
82	New Practical Aspects of Sweet Syndrome.. *American Journal of Clinical Dermatology*, **2022**, 1	7.1	5
81	An unusual case of cytotoxic peripheral T-cell lymphoma. *JAAD Case Reports*, **2015**, 1, 257-60	1.4	4
80	Non-Classic Signs of Sézary Syndrome: A Review. *American Journal of Clinical Dermatology*, **2020**, 21, 383-391	7.1	4
79	Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma. *British Journal of Dermatology*, **2018**, 178, 302-303	4	4
78	Alopecia areata after HLA-identical BMT from an affected, sibling donor. *Bone Marrow Transplantation*, **2014**, 49, 592-4	4.4	4
77	Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. *Expert Review of Hematology*, **2017**, 10, 757-760	2.8	4
76	Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1535-1536	4	4
75	Nerve growth factor in normal and psoriatic skin equivalent models. *Archives of Dermatological Research*, **1998**, 290, 610-4	3.3	4
74	Cold urticaria in a patient with mycosis fungoides. *Journal of the American Academy of Dermatology*, **2002**, 47, 608-10	4.5	4
73	High-frequency sonography of the skin. *Journal of the European Academy of Dermatology and Venereology*, **1994**, 3, 47-55	4.6	4
72	Primary cutaneous CD30(+) lymphoproliferative disorders. *JDDG - Journal of the German Society of Dermatology*, **2016**, 14, 767-82	1.2	4
71	Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. *American Journal of Clinical Dermatology*, **2021**, 1	7.1	4
70	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. *Radiotherapy and Oncology*, **2019**, 131, 88-92	5.3	3
69	Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. *Journal of Cutaneous Pathology*, **2019**, 46, 872-877	1.7	3
68	CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. *Melanoma Research*, **2011**, 21, e15-e16	3.3	3
67	Bone marrow transplantation in Jehovah's Witnesses. *Leukemia and Lymphoma*, **2004**, 45, 635-6	1.9	3
66	Curcumin for the treatment of tumor-stage mycosis fungoides. *Dermatologic Therapy*, **2017**, 30, e12511	2.2	3

65	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. *Blood*, **2016**, 128, 1826-1826	2.2	3
64	Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. *Oncotarget*, **2019**, 10, 3183-3197	3.3	3
63	Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15´years later. *International Journal of Dermatology*, **2019**, 58, e221-e222	1.7	2
62	Unmasking a T cell lymphoma: Folliculotropic mycosis fungoides with a gamma-delta phenotype. *JAAD Case Reports*, **2020**, 6, 1316-1319	1.4	2
61	CD209 monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEX system. *Photodermatology Photoimmunology and Photomedicine*, **2020**, 36, 290-298	2.4	2
60	Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. *Clinical and Experimental Dermatology*, **2018**, 43, 449-453	1.8	2
59	Mycosis fungoides occurring at the site of previous herpes zoster eruption. *Australasian Journal of Dermatology*, **2018**, 59, 217-219	1.3	2
58	Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. *JAAD Case Reports*, **2018**, 4, 175-178	1.4	2
57	Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series. *American Journal of Clinical Dermatology*, **2014**, 15, 451-6	7.1	2
56	PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. *Hematological Oncology*, **2017**, 35, 247-248	1.3	2
55	Papuloerythroderma of Ofuji associated with an indolent CD3(-), CD4(+), TCR(-) peripheral T-cell lymphoma. *Leukemia and Lymphoma*, **2013**, 54, 2059-61	1.9	2
54	Activation of HIV in Human Skin by Ultraviolet B Radiation and its Inhibition by NFB Blocking Agents¶. *Photochemistry and Photobiology*, **2007**, 74, 805-810	3.6	2
53	Photopheresis versus transimmunization?. *Leukemia and Lymphoma*, **2006**, 47, 1449	1.9	2
52	Effects of fibroblast-keratinocyte interactions on the secretion of interleukin-8. *Bulletin of Experimental Biology and Medicine*, **1996**, 121, 167-170	0.8	2
51	Phase II Multicenter Trial of Lenalidomide: Clinical and Immunomodulatory Effects in Patients with CTCL. *Blood*, **2011**, 118, 1638-1638	2.2	2
50	2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. *Blood*, **1994**, 84, 733-738	2.2	2
49	Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non- HodgkinM lymphomas, HodgkinM disease, or lymphomatoid papulosis. *Blood*, **1996**, 88, 1771-1779	2.2	2
48	Cutaneous T-Cell Lymphomas: Mycosis Fungoides and S2ary Syndrome **2013**, 287-329		2

47	RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B-CELL LYMPHOMAS. *Hematological Oncology*, **2019**, 37, 470-471	1.3	2
46	Proteomic analysis of stratum corneum in Cutaneous T-Cell Lymphomas and psoriasis. *Experimental Dermatology*, **2019**, 28, 317-321	4	2
45	Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. *Leukemia and Lymphoma*, **2019**, 60, 1079-1082	1.9	2
44	Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation. *Pediatric Dermatology*, **2018**, 35, e13-e16	1.9	2
43	Nail irregularities associated with S□ary syndrome. *Cutis*, **2019**, 103, E11-E16	0.4	2
42	Development of S□ary syndrome following the administration of dupilumab. *Dermatology Online Journal*, **2020**, 26,	1	2
41	Image Gallery: Symmetrical whirled eschars on the face in mycosis fungoides. *British Journal of Dermatology*, **2018**, 178, e224	4	1
40	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN□S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). *Hematological Oncology*, **2019**, 37, 286-288	1.3	1
39	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. *Journal of Cutaneous Medicine and Surgery*, **2017**, 21, 568-571	1.6	1
38	BRENTUXIMAB VEDOTIN VS PHYSICIAN□S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. *Hematological Oncology*, **2017**, 35, 77-78	1.3	1
37	A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability. *JAAD Case Reports*, **2017**, 3, 358-361	1.4	1
36	RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN□S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. *Hematological Oncology*, **2017**, 35, 245-247	1.3	1
35	An adolescent with granulomatous mycosis fungoides infiltrating skeletal muscle successfully treated with oral prednisone. *JAAD Case Reports*, **2017**, 3, 276-279	1.4	1
34	Concurrent chronic lymphocytic leukemia and cutaneous T cell lymphoma: a case series. *Leukemia and Lymphoma*, **2014**, 55, 2192-5	1.9	1
33	Vorinostat for the treatment of cutaneous T-cell lymphoma. *Expert Review of Dermatology*, **2010**, 5, 393-401		1
32	Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat. *Blood and Lymphatic Cancer: Targets and Therapy*, **2012**, 17	2.6	1
31	Retinoids in Cutaneous T-Cell Lymphomas. *Basic and Clinical Dermatology*, **2007**, 183-196		1
30	Vulvar Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. *International Journal of Gynecological Pathology*, **2021**, 40, 229-233	3.2	1

29	Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. *American Journal of Hematology*, **2021**, 96, E350-E353	7.1	1
28	Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation. *Pediatric Dermatology*, **2019**, 36, e23-e26	1.9	1
27	Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study. *Journal of the American Academy of Dermatology*, **2020**, 83, 1786-1789	4.5	1
26	Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 479, 377-383	5.1	1
25	Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. *Skinmed* , **2019**, 17, 406-408	0.2	1
24	Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome. *Case Reports in Nephrology*, **2020**, 2020, 8897183	0.8	0
23	Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis. *Photodermatology Photoimmunology and Photomedicine*, **2021**,	2.4	0
22	Generalised Eruptive Keratoacanthomas of Grzybowski. *Journal of Cutaneous Medicine and Surgery*, **2017**, 21, 439	1.6	
21	Important considerations for legislation banning commercial tanning beds among minors. *Clinics in Dermatology*, **2018**, 36, 104-105	3	
20	Mogamulizumab in the treatment of cutaneous T cell lymphoma. *Expert Opinion on Orphan Drugs*, **2016**, 4, 1277-1280	1.1	
19	S□ary syndrome: an overview of current and future treatment options. *Expert Opinion on Orphan Drugs*, **2014**, 2, 889-901	1.1	
18	Primary cutaneous follicle center lymphoma following deep brain stimulation implants. *Leukemia and Lymphoma*, **2013**, 54, 1806-7	1.9	
17	Rational clinical trial design in cutaneous lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2010**, 10 Suppl 2, S80-3	2	
16	Treatment of Cutaneous T-cell Lymphomas **2010**, 449-457		
15	Primary Sezary Syndrome Commonly Involves Skin Without Epidermotropism. *Journal of Cutaneous Pathology*, **2008**, 32, 85-85	1.7	
14	003UVB dose and cell cycle conditions influence the outcome of UVB-induced HIV activation. *Photodermatology Photoimmunology and Photomedicine*, **2002**, 18, 104-104	2.4	
13	Alitretinoin. *American Journal of Clinical Dermatology*, **2000**, 1, 315-316	7.1	
12	Induction of Polyclonal T-Cell Responses Against Cutaneous T-Cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA.. *Blood*, **2006**, 108, 5189-5189	2.2	

List of Publications

11	Overall Survival in Erythrodermic Cutaneous T-Cell Lymphoma: An Analysis of Prognostic Factors in a Cohort of Erythrodermic Cutaneous T-Cell Lymphoma Patients.. *Blood*, **2007**, 110, 3574-3574	2.2
10	Lymphomatoid Papulosis: Assessing Treatment Response and Associated Lymphomas in a Study of 180 Patients. *Blood*, **2015**, 126, 1487-1487	2.2
9	Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling As the Top Pathway Associated with Clinical Response. *Blood*, **2015**, 126, 3981-3981	2.2
8	Molecular and Biological Characteristics of Acquired Vorinostat-Resistant Cutaneous T-Cell Lymphoma Cells.. *Blood*, **2009**, 114, 1732-1732	2.2
7	Cutaneous T-Cell Lymphomas **2013**, 155-177	
6	Cutaneous T-Cell Lymphoma and Cutaneous B-Cell Lymphoma **2020**, 1948-1964.e5	
5	Lymphomatoid Papulosis With a Unique T Follicular Helper-Like Phenotype. *American Journal of Dermatopathology*, **2020**, 42, 776-779	0.9
4	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. *Case Reports in Oncology*, **2018**, 11, 721-728	1
3	Cutaneous T-cell lymphoma in a patient with celiac disease. *Cutis*, **2016**, 98, E1-2	0.4
2	Waistband Mycosis Fungoides: A New Clinical Variant of Early-Stage Disease. *Skinmed*, **2019**, 17, 329-332	0.2
1	Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma. *Dermatology Online Journal*, **2020**, 26,	1